Severe hyperchloremic metabolic acidosis with SGLT2 inhibitors in patients with urinary diversion

Severe hyperchloremic metabolic acidosis with SGLT2 inhibitors in patients with urinary diversion

Show other versions (1)

Urinary diversion after cystectomy using autologous intestinal segments has been the gold standard treatment in several urinary tract diseases. The most frequent metabolic consequence is hyperchloremic metabolic acidosis, due to ammonium hydrogen and chloride ions absorption in exchange for the excr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Carolina Gomes, João Barbosa Barroso, Ana Isabel Oliveira, Sofia Guerreiro Cruz, Liliana Cunha, Ana Azevedo
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Series:	Nefrología (English Edition)
Subjects:	Los inhibidores del cotransportador sodio-glucosa 2 (SGLT2) Derivación urinaria Acidosis metabólica hiperclorémica
Online Access:	http://www.sciencedirect.com/science/article/pii/S2013251425000616
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Severe hyperchloremic metabolic acidosis with SGLT2 inhibitors in patients with urinary diversion
by: Carolina Gomes, et al.
Published: (2025-05-01)

Impacto en los desenlaces intrahospitalarios con el inicio de un inhibidor del cotransportador de sodio-glucosa 2 (iSGLT2) en insuficiencia cardíaca aguda descompensada
by: Wilfredo A. Rivera-Martínez, et al.
Published: (2025-04-01)

Evaluación de las métricas derivadas del monitoreo intersticial continuo de glucosa de pacientes que usan fármacos modificadores de la enfermedad en diabetes tipo 2.
by: Andrés Alejandro Narváez Gerardino, et al.
Published: (2024-12-01)

Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
by: Riber Fabián Donoso Noroña, et al.
Published: (2024-09-01)

Predisposition to metabolic acidosis induced by topiramate Predisposição a acidose metabólica induzida por topiramato
by: MARIA AUGUSTA MONTENEGRO, et al.
Published: (2000-12-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Topiramate and severe metabolic acidosis: case report Acidose metabólica grave por topiramato: relato de caso
by: Jayme E. Burmeister, et al.
Published: (2005-06-01)

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
by: Diego Rivas‐Otero, et al.
Published: (2025-03-01)

Metabolic Acidosis: Diagnostics and Treatment
by: R. F. Tepaev, et al.
Published: (2016-11-01)

EEG Discontinuity and Neonatal Acidosis
by: J Gordon Millichap
Published: (1994-07-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Examination of a patient with renal tubular acidosis: renal tubular acidosis with hyperparathyroidism, pheochromocytoma, and multiple kidney stones: a case report
by: Marzieh Nasiri Sangari, et al.
Published: (2025-06-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)

Quadriplegia in Accidently Diagnosed Distal Renal Tubular Acidosis with Pneumonia:Case Report
by: Maryam Ghffarirahbar, et al.
Published: (2024-10-01)

Safety of SGLT2 Inhibitors and Urinary Tract Infections in Clinical Practice—A Cross-Sectional Study
by: Liana Iordan, et al.
Published: (2024-12-01)

¿Combinamos AR-GLP1 + i-SGLT2? Sí o no
by: Claudia Folino
Published: (2024-10-01)

Is the Impact of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors on Bone Metabolism and Fracture Incidence a Class or Drug Effect? A Narrative Review
by: George I. Lambrou, et al.
Published: (2025-04-01)

Metabolic Acidosis Is Associated With an Accelerated Decline of Allograft Function in Pediatric Kidney Transplantation
by: Agnieszka Prytula, et al.
Published: (2024-06-01)

Lactic acidosis in the practice of a resuscitator
by: V. V. Skvortsov, et al.
Published: (2020-06-01)

An unexpected cause of severe metabolic acidosis
by: Suzanne K. Veneman, et al.
Published: (2025-05-01)

High Anion Gap Metabolic Acidosis as a Result of 5-Oxoproline
by: Suvika Patel, et al.
Published: (2022-07-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Topiramate and Metabolic Acidosis in Infants
by: J Gordon Millichap
Published: (2002-08-01)

SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations
by: Mohammed Abdulrasak, et al.
Published: (2025-05-01)

Telmisartan-induced type 4 renal tubular acidosis: a case report
by: Thang Nguyen Ngoc, et al.
Published: (2025-06-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
by: Ji Yun Lee, et al.
Published: (2025-07-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

Venlafaxine intoxication in an adolescent presenting with severe lactic acidosis
by: İrem Eldem, et al.
Published: (2016-04-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

ACUTE KIDNEY INJURY DUE TO METFORMIN-ASSOCIATED LACTIC ACIDOSIS
by: Svilena Aleksandrova, et al.
Published: (2025-08-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)

Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator
by: Celestino Sardu, et al.
Published: (2025-06-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach: Indonesian Perspective - An Expert Opinion
by: Aida Lydia, et al.
Published: (2023-01-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

Mottling as an early sign of euglycemic ketoacidosis induced by SGLT-2 inhibitors
by: Besard Memeti, et al.
Published: (2025-03-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)